FindTrial
Sign In

Use of CA125,HE4 and Risk of ovarian malignancy(ROMA) index in ovarian cancer

Evaluation of serum HE4 , CA125 and Risk Of Ovarian Malignancy Algorithm(ROMA)for diagnosis of ovarian malignancy

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2020/09/027922
Enrollment
100
Registered
2020-09-21
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N838- Other noninflammatory disorders ofovary, fallopian tube and broad ligament

Interventions

None listed

Sponsors

Maulana Azad Medical College
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients of any age group with complex adnexal mass

Exclusion criteria

Exclusion criteria: 1. Pregnant females 2. Known cases of genital malignancy 3. Previously treated for ovarian malignancy 4. Known cases of endometriosis or pelvic tuberculosis

Design outcomes

Primary

MeasureTime frame
To independently evaluate CA-125, HE4 and the combination of HE4 and CA125 using Risk of Ovarian Malignancy Algorithm (ROMA) for the diagnosis of ovarian cancerTimepoint: At enrolment—

Secondary

MeasureTime frame
1. To see association of the tests with the type of histology of ovarian cancer 2. To see association of the tests with the stage of the ovarian cancerTimepoint: at enrollment , after biopsy or imaging and postoperatively—

Countries

India

Contacts

Public ContactDr Gauri Gandhi

Maulana Azad Medical College, New Delhi

ggandhi2004@yahoo.co.in8860209017

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026